Antiadhesion effect of the C17 glycerin ester of isoprenoid-type lipid forming a nonlamellar liquid crystal
Source abstract
Abstract
Postoperative adhesion is a relevant clinical problem that causes a variety of clinical complications after abdominal surgery. The objective of this study is to develop a liquid-type antiadhesion agent and evaluate its efficacy in preventing tissue adhesion in a rat peritoneal adhesion model. The liquid-type agent was prepared by submicron-sized emulsification of C17 glycerin ester (C17GE), squalene, pluronic F127, ethanol, and water with a high-pressure homogenizer. The primary component was C17GE, which is an amphiphilic lipid of one isoprenoid-type hydrophobic chain and can form two phases of self-assembly nonlamellar liquid crystals. The C17GE agent consisted of nanoparticles with an internal inverted hexagonal phase when evaluated by small-angle X-ray scattering (SAXS) and cryo-transmission electron microscopy (cryo-TEM). Upon contact with the biological tissue, this agent formed a thin membrane with a bioadhesive property. After this agent was applied to a sidewall injury of rats, it showed a percentage average of adhesion significantly less than that obtained with the Seprafilm® antiadhesion membrane in a rat model. Additionally, the retention of the agent prolonged at the applied site in the peritoneal cavity of rats. In conclusion, the C17GE agent is promising as an antiadhesion material. STATEMENT OF SIGNIFICANCE: Postoperative adhesion remains a common adverse effect. Although various materials have been investigated, there are few products commercially available to prevent adhesion. For the sheet-type agent, it is inconvenient to be applied through small laparotomy, especially in laparoscopic surgery. Additionally, the liquid-type agent currently used requires a complicated procedure to spray at the targeted site. Our liquid-type antiadhesion agent can form liquid crystals and act as a thin membrane-like physical barrier between the peritoneum and tissues to prevent adhesion. Indeed, the antiadhesion agent used in our present study significantly prevents adhesion compared with the antiadhesion membrane most used clinically. Moreover, our agent is highly stable by itself and easy to use in laparoscopic surgery, thus leading to a promising new candidate as an antiadhesion material.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Intestinal and Peritoneal Adhesions · Hernia repair and management · Intraperitoneal and Appendiceal Malignancies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (62)
Show source-provided references
1. Intestinal obstruction from adhesions–how big is the problem?
2. Adhesions after abdominal surgery: a systematic review of the incidence, distribution and severity10.1007/s00595-013-0591-8 ↗
3. Consequences and complications of peritoneal adhesions10.1111/j.1463-1318.2007.01358.x ↗
4. Post-operative adhesions after digestive surgery: their incidence and prevention: review of the literature10.1016/j.jviscsurg.2011.11.006 ↗
5. Efficacy and safety of sodium hyaluronate with 1,4-butanediol diglycidyl ether compared to sodium carboxymethylcellulose in preventing adhesion formation after lumbar discectomy10.14245/kjs.2015.12.2.41 ↗
6. Prevention of postoperative small bowel obstruction in gastric cancer10.1007/s00595-014-1106-y ↗
7. Preventive effect of dexamethasone gelatin sponge on the lumbosacral epidural adhesion
8. Development of gelatin flakes, a new type of anti-adhesive material: a preliminary study of in vivo rat adhesion models10.1007/s00595-013-0608-3 ↗
9. Gelatin sealing sheet for arterial hemostasis and anti-adhesion in vascular surgery: a dog model study
10. Novel technique of overlaying a poly-L: -lactic acid nanosheet for adhesion prophylaxis and fixation of intraperitoneal onlay polypropylene mesh in a rabbit model10.1007/s00464-011-1745-7 ↗
11. Tendon healing and anti-adhesion properties of electrospun fibrous membranes containing bFGF loaded nanoparticles10.1016/j.biomaterials.2013.03.026 ↗
12. Preventing intra-abdominal adhesions with polylactic acid film: an animal study10.1007/s10350-004-0748-z ↗
13. Polylactic acid nanosheets in prevention of postoperative intestinal adhesion and their effects on bacterial propagation in an experimental model10.1002/bjs.10122 ↗
14. Peritoneal adhesion prevention by a biodegradable hyaluronic acid-based hydrogel formed in situ through a cascade enzyme reaction initiated by contact with body fluid on tissue surfaces10.1016/j.actbio.2015.06.023 ↗
15. A sprayable hyaluronate/carboxymethylcellulose adhesion barrier exhibits regional adhesion reduction efficacy and does not impair intestinal healing10.1007/s11605-011-1709-1 ↗
16. The prevention of peritoneal adhesions by in situ cross-linking hydrogels of hyaluronic acid and cellulose derivatives10.1016/j.biomaterials.2006.10.021 ↗
17. Use of a modified chitosan-dextran gel to prevent peritoneal adhesions in a rat model10.1016/j.jss.2010.06.028 ↗
18. Temperature-sensitive hydrogels composed of chitosan and hyaluronic acid as injectable carriers for drug delivery10.1016/j.ejpb.2007.08.012 ↗
19. A thermosensitive chitosan-based hydrogel barrier for post-operative adhesions' prevention10.1016/j.biomaterials.2009.05.084 ↗
20. Trehalose solution protects mesothelium and reduces bowel adhesions10.1016/j.jss.2014.03.077 ↗
21. Injectable pullulan hydrogel for the prevention of postoperative tissue adhesion10.1016/j.ijbiomac.2016.02.026 ↗
22. Biodegradable and thermosensitive micelles inhibit ischemia-induced postoperative peritoneal adhesion
23. Biodegradable and thermoreversible PCLA-PEG-PCLA hydrogel as a barrier for prevention of post-operative adhesion10.1016/j.biomaterials.2011.03.046 ↗
24. Evaluation of the potential anti-adhesion effect of the PVA/Gelatin membrane10.1002/jbm.b.33066 ↗
25. Prevention of postsurgical adhesions by INTERCEED(TC7), an absorbable adhesion barrier: a prospective randomized multicenter clinical study. INTERCEED(TC7) Adhesion Barrier Study Group, Fertil Steril 51(6), 1989, 933-8.10.1016/S0015-0282(16)60721-5 ↗
26. Microsurgery alone or with INTERCEED Absorbable Adhesion Barrier for pelvic sidewall adhesion re-formation. The INTERCEED (TC7) Adhesion Barrier Study Group II
27. Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study. Seprafilm Adhesion Study Group10.1016/S0015-0282(16)58716-0 ↗
28. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study
29. The primary result of prospective randomized multicenter trial of new spray-type bio-absorbable adhesion barrier system (TCD-11091) against postoperative adhesion formation10.1007/s11605-017-3503-1 ↗
30. Oral and transdermal drug delivery systems: role of lipid-based lyotropic liquid crystals10.2147/DDDT.S103505 ↗
31. Hexosomes: a novel drug delivery system10.2174/156720110790396526 ↗
32. Cubosomes and hexosomes as versatile platforms for drug delivery10.4155/tde.15.81 ↗
33. New lipid family that forms inverted cubic phases in equilibrium with excess water: molecular structure-aqueous phase structure relationship for lipids with 5,9,13,17-tetramethyloctadecyl and 5,9,13,17-tetramethyloctadecanoyl chains10.1021/jp8029874 ↗
34. Archaebacterial lipid models: highly salt-tolerant membranes from 1,2-diphytanylglycero-3-phosphocholine10.1016/0005-2736(92)90355-P ↗
35. Molecular dynamics simulation of an archaeal lipid bilayer with sodium chloride10.1039/B611543H ↗
36. Aqueous phase behavior of lipids with isoprenoid type hydrophobic chains10.1021/jp902883q ↗
37. Advances in structural design of lipid-based nanoparticle carriers for delivery of macromolecular drugs, phytochemicals and anti-tumor agents10.1016/j.cis.2017.04.006 ↗
38. Phytantriol based smart nano-carriers for drug delivery applications10.1016/j.ejps.2017.01.035 ↗
39. Usefulness of liquid-crystal oral formulations to enhance the bioavailability and skin tissue targeting of p-amino benzoic acid as a model compound10.1016/j.ejps.2016.04.003 ↗
40. A Novel chemical enhancer approach for transdermal drug delivery with C17-monoglycerol ester liquid crystal-forming lipid10.5650/jos.ess16204 ↗
41. The phase diagram of the monoolein/water system: metastability and equilibrium aspects10.1016/S0142-9612(99)00126-X ↗
42. Current strategies and future perspectives for intraperitoneal adhesion prevention10.1007/s11605-011-1819-9 ↗
43. Abdominal adhesions: current and novel therapies10.1016/j.jss.2009.09.015 ↗
44. Advances in biomaterials for preventing tissue adhesion10.1016/j.jconrel.2017.06.020 ↗
45. Development and optimization of orally and topically applied liquid crystal drug formulations10.5650/jos.ess17032 ↗
46. Structural Investigation of bulk and dispersed inverse lyotropic hexagonal liquid crystalline phases of eicosapentaenoic acid monoglyceride10.1021/acs.langmuir.7b03078 ↗
47. Preclinical evaluation of Seprafilm bioresorbable membrane
48. Standardised models for inducing experimental peritoneal adhesions in female rats10.1155/2014/435056 ↗
49. Polymers in the prevention of peritoneal adhesions10.1016/j.ejpb.2007.03.027 ↗
50. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene10.1128/CVI.00191-06 ↗
51. Emulsified microemulsions and oil-containing liquid crystalline phases10.1021/la0482711 ↗
52. Cisplatin encapsulation generates morphologically different multicompartments in the internal nanostructures of nonlamellar liquid-crystalline self-assemblies10.1021/acs.langmuir.8b01149 ↗
53. Self-assembled lipid superstructures: beyond vesicles and liposomes10.1021/nl050678i ↗
54. Stabilising cubosomes with Tween 80 as a step towards targeting lipid nanocarriers to the blood-brain barrier10.1016/j.ejpb.2016.05.001 ↗
55. Modulatory effect of human plasma on the internal nanostructure and size characteristics of liquid-crystalline nanocarriers10.1021/acs.langmuir.5b00830 ↗
56. Polymer-dispersed bicontinuous cubic glycolipid nanoparticles10.1021/bp0498544 ↗
57. Material properties in complement activation10.1016/j.addr.2011.06.002 ↗
58. Complement monitoring of Pluronic 127 gel and micelles: suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-10010.1016/j.jconrel.2013.05.030 ↗
59. Citrem modulates internal nanostructure of glyceryl monooleate dispersions and bypasses complement activation: towards development of safe tunable intravenous lipid nanocarriers10.1016/j.nano.2015.08.003 ↗
60. A structurally diverse library of safe-by-design citrem-phospholipid lamellar and non-lamellar liquid crystalline nano-assemblies10.1016/j.jconrel.2016.08.011 ↗
61. Hexosomes formed from glycerate surfactants–formulation as a colloidal carrier for irinotecan10.1016/j.ijpharm.2006.03.010 ↗
62. Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems10.1016/j.ijpharm.2005.11.033 ↗